Approaching nicotine dependency and affecting factors in smoking cessation centers

Nicotine Vaccines for Smoking Cessation

Cigarette smoking is the leading cause of preventable disease and death in the world. Smoking was responsible for an estimated 100 million deaths in the 20 century, and is expected to cause 10 times that number in the current century. A recent study estimated that smoking accounted for 16.6% of all deaths in Canada in 2002 – a total of 37,209 deaths. The direct and indirect costs of smoking in ...

Smoking cessation and nicotine-replacement therapies

Initiatives that help smokers to quit are key components in an effective tobacco-control program. Unaided, individuals’ chances of quitting are low, but success rates are higher when smokers use nicotine-replacement therapies (NRTs) and other pharmacological therapies. The current market for NRTs worldwide is small compared with the market for cigarettes, and is mostly concentrated in high-inco...

Nicotine replacement therapy in smoking cessation.

Nicotine addiction and smoking cessation treatments

It is estimated that 29% of adults in the UK smoke (Office for National Statistics, 2000). Each year smoking kills 120 000 people (13 deaths per hour), making it the single most common preventable cause of death in Britain (Callum, 1998). Around half of all smokers will die prematurely because of their addiction (Peto et al, 1994). Their overall life expectancy is, on average, 8 years less than...

Mecamylamine (a nicotine antagonist) for smoking cessation.

BACKGROUND Mecamylamine is a nicotine antagonist (that is it blocks the effect of nicotine). The rationale for its use in smoking cessation is that it may block the rewarding effect of nicotine and thus reduce the urge to smoke. OBJECTIVES The objective of this review was to determine the effectiveness of mecamylamine in promoting smoking cessation, either alone or in combination with nicotin...